|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Oglufanide
disodium
Descrpition of
Oglufanide disodium:
Oglufanide disodium is
the disodium salt of a synthetic form of a
naturally-occurring dipeptide consisting of L-glutamic acid and
L-tryptophan with potential antiangiogenic and potential
immunomodulating activities. Oglufanide inhibits vascular
endothelial growth factor (VEGF), which may inhibit angiogenesis.
This agent has also been reported to stimulate the immune response
to hepatitic C virus and intracellular bacterial infections. Check
for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
Current developer:
Implicit Bioscience (Australia)
|
MedKoo Code#: 202064
|
|
Name:
Oglufanide disodium
|
|
CAS#:
122933-59-9 (Oglufanide,
free acid); 8030-52-2 (Oglufanide
disodium)
Synonym: NSC 334073; Oglufanide; Thymogen; Timogen;
IM 862.
IUPAC/Chemical name:
(S)-4-amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic
acid
|
|
Chemical structure: |
Theoretical analysis
|
|
|
Oglufanide free acid
Chemical Formula: C16H19N3O5
Exact Mass: 333.13247
Molecular Weight: 333.34
Elemental Analysis: C, 57.65; H, 5.75; N,
12.61; O, 24.00
Oglufanide disodium
Chemical Formula: C16H17N3Na2O5
Molecular Weight: 377.30
|
|
Availability and price:
Oglufanide
disodium
is available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
Oglufanide was originally developed to treat severe
infectious disease in Russia (where it is a registered pharmaceutical),
and was extensively studied in cancer clinical trials in the United
States before being acquired by the privately-owned Brisbane biotech
company Implicit Bioscience Pty Ltd in 2005. Oglufanide regulates the
body's innate immune response to defeat invading germs and cancer cells.
The drug is also under development by Implicit for severe respiratory
diseases such as influenza (including pandemic disease) and ovarian
cancer. Oglufanide has US Investigative New Drug status and Orphan Drug
designation for cancer. see
Company's news published in 2006.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
